Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Sumanta K. Pal, MD, elaborates on the significance of the CLEAR trial from ASCO GU 2021

Dr. Pal, Clinical Professor, Department of Medical Oncology & Therapeutics Research, Co-Director, Kidney Cancer Program, City of Hope, regarding the significance of the CLEAR trial, a three-arm study designed to compare lenvatinib plus pembrolizumab versus sunitinib and lenvatinib plus everolimus versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC)

Tags: ASCO GU Conference CoverageRenal Cell Carcinomca (RCC)

Published: 23 February 2021

Recent Videos: ASCO GU Conference Coverage

video

Eleni Efstathiou, MD, PhD, regarding the PROSPER clinical trial from ASCO GU 2021

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Eleni Efstathiou, MD, PhD, offers opinion on the ACIS clinical trial

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Eleni Efstathiou, MD, PhD, elaborates on the role of chemotherapy in mCRPC

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Eleni Efstathiou, MD, PhD, discusses the prostate-specific membrane antigen (PSMA) lutetium

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Eleni Efstathiou, MD, PhD, considers the role of precision medicine in prostate cancer

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Eleni Efstathiou, MD, PhD, regarding the preliminary analysis of belzutifan & cabozantinib in ccRCC

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Eleni Efstathiou, MD, PhD, offers a message for patients on clinical progress in prostate cancer

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Matthew Galsky, MD, shares a message for patients regarding clinical progress in bladder cancer

Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, ...

video

Matthew Galsky, MD, on the role of PD-L1 testing in previously untreated, locally advanced or mUC

Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, ...

video

Matthew Galsky, MD, elaborates on outcomes from the CheckMate 274 trial

Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, ...

Related Videos

video-image

Eleni Efstathiou, MD, PhD, regarding the PROSPER clinical trial from ASCO GU 2021

video-image

Eleni Efstathiou, MD, PhD, offers opinion on the ACIS clinical trial

video-image

Eleni Efstathiou, MD, PhD, elaborates on the role of chemotherapy in mCRPC

video-image

Eleni Efstathiou, MD, PhD, discusses the prostate-specific membrane antigen (PSMA) lutetium

video-image

Eleni Efstathiou, MD, PhD, considers the role of precision medicine in prostate cancer

video-image

Eleni Efstathiou, MD, PhD, regarding the preliminary analysis of belzutifan & cabozantinib in ccRCC

video-image

Eleni Efstathiou, MD, PhD, offers a message for patients on clinical progress in prostate cancer

video-image

Matthew Galsky, MD, shares a message for patients regarding clinical progress in bladder cancer

video-image

Matthew Galsky, MD, on the role of PD-L1 testing in previously untreated, locally advanced or mUC

video-image

Matthew Galsky, MD, elaborates on outcomes from the CheckMate 274 trial

video-image

Matthew Galsky, MD, regarding Cohort 2 of the EV-201 trial presented at ASCO GU 2021

video-image

Matthew Galsky, MD, tells us about the design and outcomes of the EV-301 trial from ASCO GU '21

video-image

Jorge A. Garcia, MD, summarizes the significance of CheckMate 9ER from ASCO GU 2021

video-image

Jorge A. Garcia, MD, on the real-world analysis of abiraterone acetate & docetaxel in mHSPC

video-image

Jorge A. Garcia, MD, offers opinion on the role of chemotherapy in the treatment of mCRPC

video-image

Jorge A. Garcia, MD, elaborates on the role of PARP inhibitors in the treatment of mCRPC

video-image

Jorge A. Garcia, MD, discusses highlights from the final analysis of the TITAN study

video-image

Sumanta K. Pal, MD, offers a message to patients regarding clinical progress in kidney cancer

video-image

Sumanta K. Pal, MD, shares thoughts on the TIVO-3 trial from ASCO GU 2021

video-image

Sumanta K. Pal, MD, offers opinion on the treatment of clear cell renal cell carcinoma

video-image

William K. Oh, MD, considers the role of PARP inhibitors in mCRPC

video-image

William K. Oh, MD, summarizes outcomes from the ACIS study as presented at ASCO GU 2021

video-image

Sumanta K. Pal, MD, regarding the quality of life outcomes from CheckMate 9ER

video-image

William K. Oh, MD, offers opinion on the final analysis of the TITAN study

video-image

Sumanta K. Pal, MD, considers the unmet needs in the treatment of papillary RCC

video-image

William K. Oh, MD, offers opinion on the role of chemotherapy in the treatment of mCRPC

video-image

Sumanta K. Pal, MD, elaborates on the design and outcomes of the PAPMET trial from ASCO GU 2021

video-image

William K. Oh, MD, on the real-world analysis of abiraterone & docetaxel in mHSPC

video-image

Robert J. Motzer, MD, elaborates on key findings from the Phase III CLEAR trial

video-image

Robert J. Motzer, MD, offers opinion on whether findings from the CLEAR trial are practice-changing

video-image

Robert J. Motzer, MD, discusses the side effect profiles of the combinations in the CLEAR trial

video-image

Robert J. Motzer, MD, speculates on the future role of combination therapy in advanced ccRCC

video-image

Robert J. Motzer, MD, considers the issue of drug resistance in treating advanced ccRCC

video-image

David A. Braun, MD, PhD, regarding the follow-up trial investigating MK-6482 in ccRCC

video-image

Jeanny B. Aragon-Ching, MD, FACP, offers opinion on the role of chemotherapy in mCRPC

video-image

David A. Braun, MD, PhD, discusses the preliminary analysis of belzutifan + cabozantinib in ccRCC

video-image

Jeanny B. Aragon-Ching, MD, FACP, elaborates on the IMvigor130 trial

video-image

Jeanny B. Aragon-Ching, MD, FACP, provides perspective on CheckMate-274

video-image

Jeanny B. Aragon-Ching, MD, FACP, elaborates on the EV-201 clinical trial

video-image

Jeanny B. Aragon-Ching, MD, FACP, shares the design and outcomes of the EV-301 clinical trial

video-image

Jeanny B. Aragon-Ching, MD, FACP, regarding the CheckMate-9ER trial presented at GU 2021

video-image

Tanya Dorff, MD, on how checkpoint inhibitors are being incorporated into mCRPC treatment algorithms

video-image

Daniel M. Geynisman, MD, on how real-world analysis influences clinical decision-making

video-image

Tanya Dorff, MD, regarding the role of CAR-T cell therapy in the management of PSCA+ mCRPC

video-image

Elisabeth Heath, MD, FACP, explains the design and outcomes of the ACIS study from ASCO GU 2021

video-image

Daniel M. Geynisman, MD, on the real-world analysis of abiraterone acetate & docetaxel in mHSPC

video-image

Tanya Dorff, MD, on the role of chemotherapy in mCRPC patients who have failed prior therapies

video-image

Elisabeth Heath, MD, FACP, provides opinion on PSA screening in prostate cancer

video-image

Daniel M. Geynisman, MD, considers implications for patients as a result of the RETAIN BLADDER trial

video-image

Tanya Dorff, MD, explains the design and outcomes of the ACIS clinical trial

video-image

Elisabeth Heath, MD, FACP, offers perspective on the KEYNOTE-365 clinical study

video-image

Daniel M. Geynisman, MD, explains the risk-adapted approach used in the RETAIN BLADDER trial

video-image

Tanya Dorff, MD, offers impressions of the updated TITAN clinical trial from ASCO GU 2021

video-image

Elisabeth Heath, MD, FACP, shares updated results of the TITAN clinical trial from ASCO GU 2021

video-image

Daniel M. Geynisman, MD, provides an overview of the RETAIN BLADDER presented at ASCO GU 2021

video-image

Thomas Powles, MD, PhD, FCRP, offers opinion on whether the results of EV-301 are practice-changing

video-image

Thomas Powles, MD, PhD, FCRP, regarding the EV-301 Phase III clinical study from ASCO GU 2021

video-image

Kim N. Chi, MD, speculates on the future role of apalutamide in the treatment of prostate cancer

video-image

Thomas Powles, MD, PhD, FCRP, tell us about the novel antibody-drug conjugate enfortumab vedotin

video-image

Kim N. Chi, MD, outlines the safety profile of apalutamide

video-image

Thomas Powles, MD, PhD, FCRP, on the impact of I-O in the management of metastatic UC

video-image

Kim N. Chi, MD, on what findings from the Phase III TITAN study mean for patients

video-image

Arlene Siefker-Radtke, MD, regarding the EV-201 Cohort 2 study & clinical implications for patients

video-image

Kim N. Chi, MD, considers the impact of the crossover design in the analysis of the TITAN study

video-image

Arlene Siefker-Radtke, MD, discusses key takeaways from the EV-301 study in urothelial cancer

video-image

Kim N. Chi, MD, regarding key highlights from the final analysis of the Phase III TITAN study

video-image

Arlene Siefker-Radtke, MD, on the management of treatment-emergent AEs & the use of FGFR inhibitors

video-image

David Braun, MD, PhD, shares how the treatment of ccRCC in the refractory setting is changing

video-image

Arlene Siefker-Radtke, MD, discusses some of the antibody drug conjugates currently in development

video-image

David Braun, MD, PhD, considers the evolving treatment landscape of 1st line ccRCC

video-image

Arlene Siefker-Radtke, MD, speculates on the role of antibody drug conjugates in the treatment of UC

video-image

David Braun, MD, PhD, offers opinion on the role of HIF-2α inhibitors in ccRCC

video-image

Eleni Efstathiou, MD, PhD, regarding patients more likely to respond to nivolumab + cabozantinib

video-image

Eleni Efstathiou, MD, PhD, offers opinion on whether CheckMate 9ER is practice-changing

video-image

Eleni Efstathiou, MD, PhD, discusses the CheckMate 9ER clinical trial presented at ESMO 2020

video-image

Laurence Albigès, MD, PhD, on patient responses to combo nivolumab + ipilimumab in 1st line RCC

video-image

Laurence Albigès, MD, PhD, offers opinion on whether CheckMate 214 is practice-changing

video-image

Laurence Albigès, MD, PhD, shares outcomes & updates from the CheckMate 214 study in advanced RCC

video-image

Cristina Suárez, MD, on patient subtype responses to combo nivolumab + cabozantinib in 1st line RCC

video-image

Cristina Suárez, MD, offers opinion on whether the CheckMate 9ER trial is practice-changing

video-image

Cristina Suárez, MD, compares the control arm of CheckMate 9ER with current 1st line RCC regimens

video-image

Cristina Suárez, MD, elaborates on the outcomes of the CheckMate 9ER study presented at ESMO 2020

video-image

Cristina Suárez, MD, on the promise of I-O in advanced renal cell carcinoma

video-image

Sumanta Kumar Pal, MD, regarding HIF-2 being the next target for novel precision cancer medicine

video-image

Sumanta Kumar Pal, MD, discusses the strategy of combining and/or sequencing Immunotherapy and TKIs in advanced RCC management

video-image

Sumanta Kumar Pal, MD, discusses his recently published work and how it has impacted approach to RCC

video-image

Sumanta Kumar Pal, MD, shares current treatment approach for a patient with advanced renal cell cancer

video-image

Rana McKay, MD, discusses factors considered when deciding which patients to get an I-O combo in RCC

video-image

Rana McKay, MD, discusses the unmet needs for clinical trials addressing non-clear cell RCC

video-image

Rana McKay, MD, explains approach to treating 2nd-line RCC patients who have received I-O combination

video-image

Rana McKay, MD, discusses the design and outcomes of the Phase 3 randomized Keynote 426 study in 1st line clear cell renal cell cancer (RCC)

video-image

Toni Choueiri, MD, describes potential importance of combining ipi/nivo for 1st line renal cell carcinoma patients

video-image

Toni Choueiri, MD, describes treatment strategies for 2nd line renal cell carcinoma

video-image

Derek Raghavan, MD, on the role of nephrectomy in the age of targeted therapies and immunotherapy

video-image

Toni Choueiri, MD, provides observations into the dynamic field of kidney cancer

video-image

Toni Choueiri, MD, considers the next steps in the further development of HIF-2 inhibitors

video-image

Toni Choueiri, MD, makes predictions for triplet combinations in the treatment of RCC

video-image

Toni Choueiri, MD, discusses approach to first line treatment of clear cell renal cell cancers

video-image

Toni Choueiri, MD, provides updates on HIF-2 alpha inhibitors in renal call cancer

video-image

Elizabeth Plimack, MD, on differentiating 1st line RCC patients when selecting a combination regimen

video-image

Elizabeth Plimack, MD, on treating 2nd line RCC patients that have received an I-0 combination in the 1st line setting

video-image

Eric Jonasch, MD, discusses the incidence of Von Hippel-Lindau Disease among RCC patients

video-image

Eric Jonasch, MD, expounds on the use of MK-6482 in both RCC and non-RCC tumors

video-image

Eric Jonasch, MD, explains the development process for MK-6482 and hopes for future studies

video-image

Eric Jonasch, MD, on the 4 year Checkmate-214 follow up investigating nivolumab + ipilimumab

video-image

Eric Jonasch, MD, considers the combination and/or sequencing IO and TKIs in advanced RCC management

video-image

Eric Jonasch, MD, recognizes interesting clinical presentations regarding RCC management at ASCO20

video-image

Elizabeth Plimack, MD, explains the design and outcomes of the Phase 3 randomized Keynote 426 study

video-image

Eric Jonasch, MD, explains MK-6482 and the tumor types it will be most effective in